
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax Inc has shown improved financial positioning with a revised revenue guidance for FY25, reflecting an increase from $1-$1.05 billion to $1.04-$1.06 billion. The company has recorded $225 million in milestones from Sanofi (SNY), with an expected additional $50 million in the fourth quarter, boosting its financial outlook and cash flow for operations. Furthermore, the working capital has strengthened to $544.7 million, demonstrating the company's ability to manage its resources effectively and focus on its core competencies within the vaccine development space.
Bears say
Novavax Inc's financial outlook is burdened by significant cash burn, with cash equivalents decreasing to $778.2 million from $938.2 million due to operational expenses, despite some offset from milestone payments and debt refinancing. The company has experienced a 17% year-over-year revenue decline, primarily attributed to the transition of lead commercial responsibility to Sanofi for the upcoming COVID season, which has also led to a drastic 55% year-over-year decrease in third-quarter revenue. Additionally, concerns persist regarding the competitiveness of Novavax's pipeline products, such as NanoFlu, as their differentiation from existing vaccines is uncertain, posing further risks to future revenue generation and overall valuation.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares